"Hela人宮頸癌細胞全年復蘇|已有STR圖譜

傳代比例：1:2-1:4(首次傳代建議1:2)

生長特性：貼壁生長

【細胞培養(yǎng)經(jīng)驗分享】啟蒙老師的重要性：一般進實驗室都有師兄師姐帶著做，他們就是你做細胞的啟蒙老師。他們的操作手法、細節(jié)、理論講解就成了你操作的準則，如營養(yǎng)液、細胞瓶的擺放位置、滅菌處理程序、開蓋手法、細胞吹打手法等等。要學會他們的正確操作，在第一次的時候就要重視。像養(yǎng)孩子一樣養(yǎng)細胞，細胞有時真的很脆弱，最好每天都去看看它，以防止出現(xiàn)培養(yǎng)箱缺水、缺二氧化碳、停電、溫度不夠等異?，F(xiàn)象，也好及時解決這些意外，避免重復實驗帶來的更大痛苦。好細胞要及時保種：細胞要分批傳代，這樣即使有一批出了問題，還有一批備用的。像后者一般人可能不容易做到。但這是我血的教訓，有一次細胞污染了，全軍覆沒。當時可后悔沒有保種。細胞跟人一樣，不同的細胞，培養(yǎng)特性是不一樣的。培養(yǎng)過程中要細細體會，不同細胞系使用不同的培養(yǎng)基和血清。

換液周期：每周2-3次

T1-73 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：４傳代；每周換液２-３次。;生長特性：貼壁生長;形態(tài)特性：成纖維細胞;相關(guān)產(chǎn)品有：PM6細胞、C12細胞、CL MC/9細胞

PG-LH7 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：RSMC細胞、T/GHA-VSMC細胞、CAL 78細胞

Virginia Mason Research Center-Lung Cancer D Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：H211細胞、CLL-CII細胞、bEnd.3[BEND3]細胞

背景信息：HeLa是第一個來自人體組織經(jīng)連續(xù)培養(yǎng)獲得的非整倍體上皮樣細胞系，它由GeyGO等在１９５１年從３１歲女性黑人的宮頸癌組織建立。經(jīng)原始組織切片重新觀察，Jones等將其診斷為腺癌。已知該細胞系含有人乳頭狀瘤病毒HPV１８序列，需在２級生物安全防護臺操作。該細胞角蛋白陽性，p５３表達量較低，但表達正常水平的pRB（視網(wǎng)膜母細胞瘤抑制因子）。

Hela人宮頸癌細胞全年復蘇|已有STR圖譜

產(chǎn)品包裝：復蘇發(fā)貨：T25培養(yǎng)瓶(一瓶)或凍存發(fā)貨：1ml凍存管(兩支)

DSMZ菌株保藏中心成立于1969年，是德國的國家菌種保藏中心。該中心一直致力于細菌、真菌、質(zhì)粒、抗菌素、人體和動物細胞、植物病毒等的分類、鑒定和保藏工作。DSMZ菌種保藏中心是歐洲規(guī)模最大的生物資源中心，保藏有動物細胞500多株。Riken BRC成立于1920年，是英國的國家菌種保藏中心。該中心一直致力于細菌、真菌、植物病毒等的分類、鑒定和保藏工作。日本Riken BRC(Riken生物資源保藏中心)是全球三大典型培養(yǎng)物收集中心之一。Riken保藏中心提供了很多細胞系。在世界范圍內(nèi)，這些細胞系，都在醫(yī)學、科學和獸醫(yī)中具有重要意義。Riken生物資源中心支持了各種學術(shù)、健康、食品和獸醫(yī)機構(gòu)的研究工作，并在世界各地不同組織的微生物實驗室和研究機構(gòu)中使用。

SCI1 Cells;背景說明：胚胎；自發(fā)永生;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HC11 Mammary Epithelium細胞、SK-NSH細胞、PIGI細胞

LM-TK- Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：RPTC細胞、ID8細胞、GC-2spd(ts)細胞

CoCL3 Cells;背景說明：DLD-１是１９７７-１９７９年間D.L.Dexter和同事分離的兩株結(jié)直腸腺癌細胞株中的一株。在ATCC和其它地方進行的DNAfingerprinting和染色體組型分析表明這株細胞與HCT-１５(CCL-２２５)相似，說明這兩者是來自同一個人的不同克隆。他們的遺傳起源可通過DNAfingerprinting證實，但染色體組型分析顯示它們?nèi)狈θ旧w標記一致改變或數(shù)目上一致改變。細胞的CSAp陰性(CSAp-)。DLD-１細胞的p５３抗原表達呈陽性(p５３抗原產(chǎn)生了一個C->;傳代方法：消化５分鐘。１：２。４-５天長滿。;生長特性：貼壁生長;形態(tài)特性：上皮細胞樣;相關(guān)產(chǎn)品有：H1355細胞、H2228細胞、T-ALL1細胞

4e2 Cells(提供STR鑒定圖譜)

來源說明：細胞主要來源ATCC、ECACC、DSMZ、RIKEN等細胞庫

物種來源：人源、鼠源等其它物種來源

Hela人宮頸癌細胞全年復蘇|已有STR圖譜

形態(tài)特性：上皮細胞樣

貼壁細胞消化傳代時通常采用兩種方法：一、加入胰酶等細胞脫落后，再加培養(yǎng)基中止胰酶作用，離心傳代；二、加入胰酶后，鏡下觀察待細胞始脫落時，棄胰酶，加培養(yǎng)分瓶。但前者太麻煩，而后者有可能對細胞施加胰酶選擇，因為總是貼壁不牢的細胞先脫落，對腫瘤細胞來說，這部分細胞有可能是惡性程度較GAO的細胞亞群。一種簡單的消化傳代方法。加入PBS洗去血清或加入胰酶先中和血清的作用(３０s)，棄之，再加入適量胰酶作用１０s-４０s(根據(jù)細胞消化的難易程度)，棄之，這樣依賴殘余的胰酶就可將細胞消化單細胞。對于較難消化的細胞，可以用２%利多卡因消化５-８分鐘，然后再棄去，加培養(yǎng)基吹打也可以，對細胞的影響不大。不用PBS也不用Hanks洗，只要把舊培養(yǎng)吸的干凈一點，直接加酶消化應該不會有什么問題。棄培養(yǎng)后，用０.０４%的EDA沖洗一次，再用１/４v的０.０４%的EDA室溫孵育５min，棄取大部分EDA，加入與剩余EDA等量的胰酶(預熱)總體積１/１０v。消化到有細胞脫落。不過有人說EDA對細胞不HAO，有證據(jù)嗎？培養(yǎng)的BASMC：倒掉舊培養(yǎng)加入少量胰酶沖一下，倒掉再加入０.１２５-０.２５%胰酶約６-１０滴或１ml(２５ml bole)消化再加入適量新培養(yǎng)基中和，并分瓶這種方法簡單、省事；效果很HAO并且不損失細胞！

LM3 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：HCC1500細胞、UCLA-SO-M14細胞、H-35細胞

WPMY-1 Cells;背景說明：肌成纖維基質(zhì)細胞株,WPMY-１,與RWPE-１cells(ATCCCRL-１１６０９)一樣，來源于同一張成人前列腺組織切片的周圍區(qū)域的基質(zhì)細胞。通過一個pRSTV質(zhì)料結(jié)構(gòu)，用SV４０大T抗原對基質(zhì)細胞進行永生化。WPMY-１細胞，與RWPE-１細胞及其它上皮細胞衍生株一樣，屬于來源于同一個前列腺的一系列細胞株。由于它們來源于同一個前列腺的周圍區(qū)域，WPMY-１細胞株對于研究分泌和基質(zhì)與上皮細胞相互作用尤其有用。;傳代方法：消化３-５分鐘。１：２。３天內(nèi)可長滿。;生長特性：貼壁生長;形態(tài)特性：成肌細胞;相關(guān)產(chǎn)品有：8226細胞、K7M2-WT細胞、VM Cub 1細胞

BEAS2B Cells;背景說明：從一位非癌個體的正常人支氣管上皮病理切片分離出上皮細胞。這些細胞用腺病毒１２-SV４０病毒雜交病毒感染并克隆。DEAS-２B細胞保留了對血清反應進行鱗關(guān)分化的能力，并有用于篩選誘導或影響分化及致癌的化學或生物制劑。細胞角蛋白及SV４０抗原染色陽性。;傳代方法：消化３-５分鐘。１：２。３天內(nèi)可長滿;生長特性：貼壁生長;形態(tài)特性：上皮細胞樣;相關(guān)產(chǎn)品有：JOSK-M細胞、MCA 38細胞、WM-239-A細胞

SNU-484 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２傳代;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：T.T細胞、KTC-1細胞、EBNA293細胞

NCI-H3255 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２傳代;生長特性：貼壁生長　;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：CATH-a細胞、C8166-CD4細胞、H-196細胞

HCFB（HCF） Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：WEHI-231細胞、MG63細胞、OVCAR 420細胞

HDQP1 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Tissue Culture-1細胞、HuP-T4細胞、Ect1/E6E7細胞

D-341 Med Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：每周換液２-３次。;生長特性：懸浮生長;形態(tài)特性：髓母細胞樣;相關(guān)產(chǎn)品有：OVCAR8/ADR細胞、EOC-20細胞、HuCC-T1細胞

H740 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Neuro2a細胞、SUM-190細胞、IOSE80細胞

PK136 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NFS60細胞、Vero-76細胞、Institute for Medical Research-90細胞

CHP-100 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：PC9細胞、CAL-33細胞、HPDE6c7細胞

IEC-6 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮細胞樣;相關(guān)產(chǎn)品有：AdHek細胞、OCI-LY-7細胞、Hs 839.T細胞

SW 403 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２—１：６傳代，每周換液２-３次;生長特性：貼壁生長;形態(tài)特性：上皮細胞;相關(guān)產(chǎn)品有：NBL_S細胞、4T1-LUC細胞、A375細胞

MUTZ1 Cells;背景說明：骨髓增生異常綜合征；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：P3-X63Ag8細胞、Human Epithelioma-2細胞、HITT15細胞

Tu-177 Cells;背景說明：喉鱗癌;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：MUG-Chor1細胞、NIH:OVCAR-10細胞、WM2664細胞

MLA 144 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：ATDC-5細胞、CAL 51細胞、NCI-H1650細胞

GC-1spg Cells;背景說明：精原細胞；SV４０轉(zhuǎn)化；BALB/c;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SK.MEL.2細胞、NCI-H1299細胞、YES 2細胞

Abcam HCT 116 RNF2 KO Cells(提供STR鑒定圖譜)

AG08182 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line GST067 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line XB130 Cells(提供STR鑒定圖譜)

BMS2 Cells(提供STR鑒定圖譜)

CMM8 Cells(提供STR鑒定圖譜)

DA03635 Cells(提供STR鑒定圖譜)

deltaTCAR-3 Cells(提供STR鑒定圖譜)

GM02587 Cells(提供STR鑒定圖譜)

SK-Col-1 Cells;背景說明：該細胞來源于結(jié)直腸病人的轉(zhuǎn)移性腹水。;傳代方法：１：２-１：３傳代，每周２-３次。;生長特性：貼壁生長;形態(tài)特性：上皮細胞樣;相關(guān)產(chǎn)品有：H-1838細胞、NIE-115細胞、TYK-nu細胞

HO1-N-1 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：143TK-細胞、NCIH847細胞、YD15細胞

KOPN-8 Cells;背景說明：B淋巴細胞白血?。慌?傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NCI-H1954細胞、FRO 81-2細胞、SW 1088細胞

Karpas 299 Cells;背景說明：間變性大細胞淋巴瘤；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HNE-1細胞、AML-12細胞、RINm5F細胞

3 LL Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：UM-UC14細胞、NCI-H1954細胞、GM03671細胞

BT 549 Cells;背景說明：該細胞１９７８年由W.G.Coutinho和E.Y.Lasfargues建系，源自一位７２歲患有乳腺導管癌的白人女性，來源組織包括乳頭及浸潤導管。該細胞形態(tài)包括上皮樣細胞及多核巨細胞，可分泌一種粘性物質(zhì)。;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：DU4475細胞、HS-729細胞、Mouse podocyte細胞

NBL-S Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：CZ-1細胞、H-1395細胞、U-373MG ATCC細胞

OUMS-23 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：210RCY3-Ag1.2.3細胞、SF 763細胞、COLO206F細胞

Hela人宮頸癌細胞全年復蘇|已有STR圖譜

NP69SV40T Cells;背景說明：鼻咽；上皮細胞；SV４０轉(zhuǎn)化;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：MC3T3E1細胞、HOEC細胞、MGHU1細胞

TE-85 Cells;背景說明：骨肉瘤；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Calf Pulmonary Artery 47細胞、MDCK Type II細胞、COLO-320細胞

SKMEL-24 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：４傳代，２-３天換液１次。;生長特性：貼壁生長;形態(tài)特性：星形的;相關(guān)產(chǎn)品有：MDA-134細胞、AE 1201細胞、MV4II細胞

NCI H2106 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：每周換液２次。;生長特性：懸浮生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：IPLB-SF-21細胞、Human podocyte細胞、TE671/RD細胞

PLA 802 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：MCF-7ADR細胞、Fukuoka University-Malignant mixed Mullerian Tumor-1細胞、MGH-UI細胞

TALL-1 [Human adult T-ALL] Cells;背景說明：該細胞源于一名復發(fā)T-ALL（急性T淋巴細胞性白血?。┑膬和耐庵苎痪哂泻軓姷募毎拘?，體內(nèi)體外實驗中都能破壞腫瘤細胞；IL-２可使細胞更好地生長；α/β TCR陽性，γ/δ TCR陰性；可產(chǎn)生IFNγ、TNF-α和GM-CSF。;傳代方法：維持細胞密度在４×１０５-１×１０６ cells/ml之間，２-３天換液１次　;生長特性：懸浮生長;形態(tài)特性：淋巴母細胞;相關(guān)產(chǎn)品有：NCI-1155細胞、H-2052細胞、Panc05.04細胞

OCI-Ly 7 Cells;背景說明：彌漫大B淋巴瘤；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：H220細胞、253J-BV細胞、Tsup-1細胞

GM19813 Cells(提供STR鑒定圖譜)

HAP1 IRAK2 (-) 2 Cells(提供STR鑒定圖譜)

PC-14 Cells;背景說明：肺腺癌；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SW 982細胞、DV90細胞、C33A細胞

CEM-T4 Cells;背景說明：急性T淋巴細胞白血?。慌?傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：MDA-MB 468細胞、OCI-AML-2細胞、MDCK (NBL-2)細胞

Biologics Standards-Cercopithecus-1 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：H-810細胞、KAT-5細胞、MB39細胞

Saos2 Cells;背景說明：該細胞是FoghJ和TrempeG分離和鑒定的眾多人類腫瘤細胞系中的一種；該細胞來自一位１１歲的白人女性的骨肉瘤組織?；颊呓?jīng)過放療以及甲喋呤、阿霉素、長春新堿、環(huán)磷酰胺和aramycin-C等多種藥物治療。該細胞在免疫抑制小鼠中不致瘤，細胞表達表皮生長因子EGF受體、轉(zhuǎn)化生長因子β（１型和２型）受體。;傳代方法：１：２-１：４傳代；每周１-２次。;生長特性：貼壁生長;形態(tài)特性：上皮樣；多角形;相關(guān)產(chǎn)品有：BHK21細胞、CL MC/9細胞、RH-30細胞

HCE Cells;背景說明：角膜上皮細胞；Ad-SV４０轉(zhuǎn)化；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HEC-1-A細胞、SMA560細胞、LUDLU-1細胞

HPAF-I Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：KM.12細胞、HC11 Mammary Epithelium細胞、Hs 832(C).T細胞

Karpas-422 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Colon 38細胞、T.T細胞、Caco-2/ATCC細胞

NGP Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：CEM-C1細胞、K299細胞、MRC-9細胞

HPS0846 Cells(提供STR鑒定圖譜)

JNUCK-2 Cells(提供STR鑒定圖譜)

MDCC-HP28 Cells(提供STR鑒定圖譜)

ND41016 Cells(提供STR鑒定圖譜)

PSF [Pelodiscus] Cells(提供STR鑒定圖譜)

Ubigene HeLa UBE3C KO Cells(提供STR鑒定圖譜)

XPH4PV Cells(提供STR鑒定圖譜)

HG01101 Cells(提供STR鑒定圖譜)

TW-039 Cells;背景說明：鼻咽癌;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：RT-4細胞、102PT細胞、GalK 1細胞

Hep-G2/C3A Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：３—１：６傳代，每周換液２次;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：alpha TC1-6細胞、BJA-B-1細胞、aTC1-6細胞

NK62a Cells;背景說明：這株細胞有EB病毒基因組。;傳代方法：１：２傳代。３天內(nèi)可長滿。;生長特性：懸浮生長 ;形態(tài)特性：淋巴母細胞樣;相關(guān)產(chǎn)品有：OV-1063細胞、ZYM-SVEC01細胞、PG-LH7細胞

Cloudman S91 melanoma clone M-3 Cells;背景說明：黑色素瘤；雄性；DBA;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：451Lu細胞、BNL CL.2細胞、HBL-1 [Human diffuse large B-cell lymphoma]細胞

SNU-C2B Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：MDA-MB-435細胞、H-82細胞、HuLEC-5a細胞

SNU-C2B Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：MDA-MB-435細胞、H-82細胞、HuLEC-5a細胞

H-35 Cells;背景說明：在糖皮質(zhì)激素、胰島素或cAMP衍生物的誘導下可以產(chǎn)生酪酸基轉(zhuǎn)移酶；可被逆轉(zhuǎn)錄病毒感染；可產(chǎn)生白蛋白、轉(zhuǎn)鐵蛋白、凝血酶原；在AxC大鼠中可以成瘤。;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：KP 4細胞、SUDHL2細胞、BSC1細胞

H647 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：３-１：６傳代；每周換液２次。;生長特性：貼壁生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：DMS-273細胞、FRhK4細胞、Reuber-H-35 hepatoma細胞

RA Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：T47D細胞、NCIH2291細胞、MV522細胞

Nb2 Cells;背景說明：惡性淋巴瘤；雄性；Nb;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：C-4I細胞、C32-mel細胞、U-251MG細胞

SNUC2A Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：每周兩次換液;生長特性：松散附著、多單元的聚合;形態(tài)特性：上皮細胞樣;相關(guān)產(chǎn)品有：A 549細胞、Panc_02_03細胞、Michigan Cancer Foundation-12A細胞

SNU-719 Cells;背景說明：胃癌；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HcerEpic細胞、P36細胞、Sp2/0-Ag14細胞

SK-GT-4 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：6-10B細胞、H1963細胞、M2-10B4細胞

V 79-4 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：FHs 74 Int細胞、K 562細胞、AU-565細胞

SHSY-5Y Cells;背景說明：據(jù)報道，該細胞的密度可高達１×１０６cells/cm２，具有中等水平的多巴胺β羥化酶的活性。;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：HEL-1細胞、SKLMS-1細胞、Human Corneal Epithelial cells-Transformed細胞

SMS-KCN-A Cells(提供STR鑒定圖譜)

CMT-93 Cells;背景說明：結(jié)腸癌；C５７BL/ICRF;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Bac1 2F5細胞、D341MD細胞、H1105細胞

HLE-B3 Cells;背景說明：晶狀體；Ad１２-SV４０轉(zhuǎn)化；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：2PK-3細胞、HTSMC細胞、RPE-hTERT細胞

3T3-A31 Cells;背景說明：胚胎；成纖維；自發(fā)永生；雄性；BALB/c;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：RBE細胞、Sun Yat-sen university Ophtalmic center-Retinoblastoma 50細胞、SupB15WT細胞

BV-2 Cells;背景說明：源于C５７BL/６小鼠小膠質(zhì)細胞，表達核v-myc、染色體v-raf癌基因，表面表達envgp７０抗原，在形態(tài)學、表型及功能上有吞噬細胞的特征。;傳代方法：１：６傳代；２-３天１次。;生長特性：半貼壁生長;形態(tài)特性：多形型;相關(guān)產(chǎn)品有：SKG IIIa細胞、INS1-E細胞、Mo7e細胞

U-87 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：LLC-WRC 256細胞、TE-12細胞、McArdle RH-7777細胞

EFM-192C Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：C-33A細胞、MDAPC2B細胞、293-H細胞

CMEC/D3 Cells;背景說明：腦微血管；內(nèi)皮 Cells;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：DB細胞、GM00215A細胞、FBHE細胞

HNEpC Cells;背景說明：鼻粘膜；上皮 Cells;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Jurkat-77細胞、M-NFS-60細胞、C4-I細胞

Hela人宮頸癌細胞全年復蘇|已有STR圖譜

Reuber-H-35 hepatoma Cells;背景說明：在糖皮質(zhì)激素、胰島素或cAMP衍生物的誘導下可以產(chǎn)生酪酸基轉(zhuǎn)移酶；可被逆轉(zhuǎn)錄病毒感染；可產(chǎn)生白蛋白、轉(zhuǎn)鐵蛋白、凝血酶原；在AxC大鼠中可以成瘤。;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：HCC-1588細胞、MPC5細胞、SW-527細胞

SUM190 Cells;背景說明：乳腺癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SW 780細胞、L-929細胞、BALB 3T3 clone A31細胞

Kit-225-K6 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：OVCA-420細胞、H1092細胞、SUDHL-8細胞

TSU-Pr1 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮細胞樣;相關(guān)產(chǎn)品有：H1568細胞、CMT 93細胞、HME-1細胞

H1155 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：每周換液２-３次。;生長特性：懸浮生長;形態(tài)特性：上皮細胞;相關(guān)產(chǎn)品有：SK UT 1細胞、MH-22a細胞、RCC4細胞

16HBE Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２傳代;生長特性：貼壁生長　;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：OCI Ly19細胞、MOLT 3細胞、MDA 1386細胞

BayGenomics ES cell line RRN258 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line YHA367 Cells(提供STR鑒定圖譜)

H280-4 Cells(提供STR鑒定圖譜)

PA317 LXSN 16E6E7 Cells(提供STR鑒定圖譜)

AFRC MAC 22 Cells(提供STR鑒定圖譜)

HOS-143B/DOXR8 Cells(提供STR鑒定圖譜)

" "PubMed=13261081

Moore A.E., Sabachewsky L., Toolan H.W.

Culture characteristics of four permanent lines of human cancer cells.

Cancer Res. 15:598-602(1955)

PubMed=16589695; DOI=10.1073/pnas.41.7.432; PMCID=PMC528114

Puck T.T., Marcus P.I.

A rapid method for viable cell titration and clone production with HeLa cells in tissue culture: the use of X-irradiated cells to supply conditioning factors.

Proc. Natl. Acad. Sci. U.S.A. 41:432-437(1955)

PubMed=14031339

Katzberg A.A.

The effect of space flights on living human cells aboard Discoverer XVIII.

Tech. Doc. Rep. SAMTDR USAF Sch. Aerosp. Med. 62:43.1-43.4(1962)

PubMed=14185313; DOI=10.1126/science.146.3641.241

Cell Culture Collection Committee

Animal cell strains. The Cell Culture Collection Committee has assembled and certified 23 strains of animal cells.

Science 146:241-243(1964)

PubMed=5668122; DOI=10.3181/00379727-128-33119

Peterson W.D. Jr., Stulberg C.S., Swanborg N.K., Robinson A.R.

Glucose-6-phosphate dehydrogenase isoenzymes in human cell cultures determined by sucrose-agar gel and cellulose acetate zymograms.

Proc. Soc. Exp. Biol. Med. 128:772-776(1968)

DOI=10.1007/BF02618370

Stulberg C.S., Coriell L.L., Kniazeff A.J., Shannon J.E.

The animal cell culture collection.

In Vitro 5:1-16(1970)

PubMed=4942173; DOI=10.1097/00006250-197112000-00028

Jones H.W. Jr., McKusick V.A., Harper P.S., Wuu K.-D.

George Otto Gey (1899-1970). The HeLa cell and a reappraisal of its origin.

Obstet. Gynecol. 38:945-949(1971)

DOI=10.1007/978-1-4757-1647-4_13

Biedler J.L.

Chromosome abnormalities in human tumor cells in culture.

(In book chapter) Human tumor cells in vitro; Fogh J. (eds.); pp.359-394; Springer; New York; USA (1975)

PubMed=1246620; DOI=10.1126/science.1246620

Hsu S.H., Schacter B.Z., Delaney N.L., Miller T.B., McKusick V.A., Kennett R.H., Bodmer J.G., Young D., Bodmer W.F.

Genetic characteristics of the HeLa cell.

Science 191:392-394(1976)

PubMed=77569; DOI=10.1111/j.1399-0039.1978.tb01259.x

Espmark J.A., Ahlqvist-Roth L., Sarne L., Persson A.

Tissue typing of cells in culture. III. HLA antigens of established human cell lines. Attempts at typing by the mixed hemadsorption technique.

Tissue Antigens 11:279-286(1978)

PubMed=6256643; DOI=10.1038/288724a0

Day R.S. 3rd, Ziolkowski C.H.J., Scudiero D.A., Meyer S.A., Lubiniecki A.S., Girardi A.J., Galloway S.M., Bynum G.D.

Defective repair of alkylated DNA by human tumour and SV40-transformed human cell strains.

Nature 288:724-727(1980)

PubMed=6935474; DOI=10.1093/jnci/66.2.239

Wright W.C., Daniels W.P., Fogh J.

Distinction of seventy-one cultured human tumor cell lines by polymorphic enzyme analysis.

J. Natl. Cancer Inst. 66:239-247(1981)

PubMed=6358339; DOI=10.1093/jhmas/38.4.415

Brown R.W., Henderson J.H.M.

The mass production and distribution of HeLa cells at Tuskegee Institute, 1953-55.

J. Hist. Med. Allied Sci. 38:415-431(1983)

PubMed=6401685; DOI=10.1007/BF02617989

Halton D.M., Peterson W.D. Jr., Hukku B.

Cell culture quality control by rapid isoenzymatic characterization.

In Vitro 19:16-24(1983)

PubMed=6825208; DOI=10.1093/carcin/4.2.199

Yarosh D.B., Foote R.S., Mitra S., Day R.S. 3rd

Repair of O6-methylguanine in DNA by demethylation is lacking in Mer- human tumor cell strains.

Carcinogenesis 4:199-205(1983)

PubMed=2983228; DOI=10.1038/314111a0

Schwarz E., Freese U.-K., Gissmann L., Mayer W., Roggenbuck B., Stremlau A., zur Hausen H.

Structure and transcription of human papillomavirus sequences in cervical carcinoma cells.

Nature 314:111-114(1985)

PubMed=2990217; PMCID=PMC1888002

Yee C., Krishnan-Hewlett I., Baker C.C., Schlegel R., Howley P.M.

Presence and expression of human papillomavirus sequences in human cervical carcinoma cell lines.

Am. J. Pathol. 119:361-366(1985)

CLPUB00262

Gold M.

A conspiracy of cells. One woman's immortal legacy and the medical scandal it caused.

(In book) ISBN 9780887060991; pp.1-171; State University of New York Press; Albany; USA (1986)

PubMed=3518877; DOI=10.3109/07357908609038260

Fogh J.

Human tumor lines for cancer research.

Cancer Invest. 4:157-184(1986)

PubMed=3028716; DOI=10.1159/000132342

Popescu N.C., DiPaolo J.A., Amsbaugh S.C.

Integration sites of human papillomavirus 18 DNA sequences on HeLa cell chromosomes.

Cytogenet. Cell Genet. 44:58-62(1987)

PubMed=3180844; DOI=10.1159/000132579

Chen T.-R.

Re-evaluation of HeLa, HeLa S3, and HEp-2 karyotypes.

Cytogenet. Cell Genet. 48:19-24(1988)

PubMed=3371749; DOI=10.1016/0090-8258(88)90029-7

Grenman S.E., Shapira A., Carey T.E.

In vitro response of cervical cancer cell lines CaSki, HeLa, and ME-180 to the antiestrogen tamoxifen.

Gynecol. Oncol. 30:228-238(1988)

PubMed=1522048; DOI=10.1007/BF02634140

Kataoka E., Honma M., Ohnishi K., Sofuni T., Mizusawa H.

Application of highly polymorphic DNA markers to the identification of HeLa cell sublines.

In Vitro Cell. Dev. Biol. Anim. 28:553-556(1992)

PubMed=8380785; DOI=10.1006/gyno.1993.1016

Iwasaka T., Oh-uchida M., Matsuo N., Yokoyama M., Fukuda K., Hara K., Fukuyama K., Hori K., Sugimori H.

Correlation between HPV positivity and state of the p53 gene in cervical carcinoma cell lines.

Gynecol. Oncol. 48:104-109(1993)

PubMed=9892199

Macville M.V.E., Schrock E., Padilla-Nash H.M., Keck C., Ghadimi B.M., Zimonjic D.B., Popescu N.C., Ried T.

Comprehensive and definitive molecular cytogenetic characterization of HeLa cells by spectral karyotyping.

Cancer Res. 59:141-150(1999)

PubMed=10423141; DOI=10.1099/0022-1317-80-7-1725

Meissner J.D.

Nucleotide sequences and further characterization of human papillomavirus DNA present in the CaSki, SiHa and HeLa cervical carcinoma cell lines.

J. Gen. Virol. 80:1725-1733(1999)

PubMed=11416159; DOI=10.1073/pnas.121616198; PMCID=PMC35459

Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G., Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R., Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.

Short tandem repeat profiling provides an international reference standard for human cell lines.

Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001)

PubMed=11668190; DOI=10.1177/002215540104901105

Quentmeier H., Osborn M., Reinhardt J., Zaborski M., Drexler H.G.

Immunocytochemical analysis of cell lines derived from solid tumors.

J. Histochem. Cytochem. 49:1369-1378(2001)

PubMed=12001993; DOI=10.1038/nrc775

Masters J.R.W.

HeLa cells 50 years on: the good, the bad and the ugly.

Nat. Rev. Cancer 2:315-319(2002)

PubMed=12793746; DOI=10.1269/jrr.43.s133

Ohnishi T., Ohnishi K., Takahashi A., Taniguchi Y., Sato M., Nakano T., Nagaoka S.

Detection of DNA damage induced by space radiation in Mir and space shuttle.

J. Radiat. Res. 43 Suppl. 1:S133-S136(2002)

PubMed=12661003; DOI=10.1002/gcc.10196

Seitz S., Wassmuth P., Plaschke J., Schackert H.K., Karsten U., Santibanez-Koref M.F., Schlag P.M., Scherneck S.

Identification of microsatellite instability and mismatch repair gene mutations in breast cancer cell lines.

Genes Chromosomes Cancer 37:29-35(2003)

PubMed=15302935; DOI=10.1073/pnas.0404720101; PMCID=PMC514446

Beausoleil S.A., Jedrychowski M.P., Schwartz D., Elias J.E., Villen J., Li J.-X., Cohn M.A., Cantley L.C., Gygi S.P.

Large-scale characterization of HeLa cell nuclear phosphoproteins.

Proc. Natl. Acad. Sci. U.S.A. 101:12130-12135(2004)

PubMed=15531914; DOI=10.1038/sj.onc.1208235

Baldus S.E., Schwarz E., Lohrey C., Zapatka M., Landsberg S., Hahn S.A., Schmidt D., Dienes H.-P., Schmiegel W.H., Schwarte-Waldhoff I.

Smad4 deficiency in cervical carcinoma cells.

Oncogene 24:810-819(2005)

PubMed=15901131; DOI=10.1016/j.prp.2005.01.002

Murai Y., Hayashi S., Takahashi H., Tsuneyama K., Takano Y.

Correlation between DNA alterations and p53 and p16 protein expression in cancer cell lines.

Pathol. Res. Pract. 201:109-115(2005)

PubMed=17311676; DOI=10.1186/1471-2164-8-53; PMCID=PMC1805756

Kloth J.N., Oosting J., van Wezel T., Szuhai K., Knijnenburg J., Gorter A., Kenter G.G., Fleuren G.J., Jordanova E.S.

Combined array-comparative genomic hybridization and single-nucleotide polymorphism-loss of heterozygosity analysis reveals complex genetic alterations in cervical cancer.

BMC Genomics 8:53.1-53.13(2007)

PubMed=19450234; DOI=10.2144/000113089; PMCID=PMC2696096

Rahbari R., Sheahan T., Modes V., Collier P., Macfarlane C.M., Badge R.M.

A novel L1 retrotransposon marker for HeLa cell line identification.

BioTechniques 46:277-284(2009)

PubMed=19722756; DOI=10.5858/133.9.1463

Lucey B.P., Nelson-Rees W.A., Hutchins G.M.

Henrietta Lacks, HeLa cells, and cell culture contamination.

Arch. Pathol. Lab. Med. 133:1463-1467(2009)

CLPUB00377

Skloot R.L.

The immortal life of Henrietta Lacks.

(In book) ISBN 9781400052172; pp.1-400; Random House; New York; USA (2010)

CLPUB00468

Javitt G.H.

Why not take all of me? Reflections on the immortal life of Henrietta Lacks and the status of participants in research using human specimens.

Minn. J. Law Sci. Technol. 11:713-755(2010)

PubMed=19941903; DOI=10.1016/j.jviromet.2009.11.022

Karger A., Bettin B., Lenk M., Mettenleiter T.C.

Rapid characterisation of cell cultures by matrix-assisted laser desorption/ionisation mass spectrometric typing.

J. Virol. Methods 164:116-121(2010)

PubMed=21269460; DOI=10.1186/1752-0509-5-17; PMCID=PMC3039570

Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Burckstummer T., Bennett K.L., Superti-Furga G., Colinge J.

Initial characterization of the human central proteome.

BMC Syst. Biol. 5:17.1-17.13(2011)

PubMed=22068331; DOI=10.1038/msb.2011.81; PMCID=PMC3261714

Nagaraj N., Wisniewski J.R., Geiger T., Cox J., Kircher M., Kelso J., Paabo S., Mann M.

Deep proteome and transcriptome mapping of a human cancer cell line.

Mol. Syst. Biol. 7:548-548(2011)

PubMed=21937730; DOI=10.1074/mcp.M111.011429; PMCID=PMC3316722

Boisvert F.-M., Ahmad Y., Gierlinski M., Charriere F., Lamont D., Scott M., Barton G., Lamond A.I.

A quantitative spatial proteomics analysis of proteome turnover in human cells.

Mol. Cell. Proteomics 11:M111.011429-M111.011429(2012)

PubMed=22278370; DOI=10.1074/mcp.M111.014050; PMCID=PMC3316730

Geiger T., Wehner A., Schaab C., Cox J., Mann M.

Comparative proteomic analysis of eleven common cell lines reveals ubiquitous but varying expression of most proteins.

Mol. Cell. Proteomics 11:M111.014050-M111.014050(2012)

PubMed=22412903; DOI=10.1371/journal.pone.0032667; PMCID=PMC3296745

Vazquez-Mena O., Medina-Martinez I., Juarez-Torres E., Barron V., Espinosa A., Villegas-Sepulveda N., Gomez-Laguna L., Nieto-Martinez K., Orozco L., Roman-Bassaure E., Munoz Cortez S., Borges Ibanez M., Venegas-Vega C.A., Guardado-Estrada M., Rangel-Lopez A., Kofman S., Berumen J.

Amplified genes may be overexpressed, unchanged, or downregulated in cervical cancer cell lines.

PLoS ONE 7:E32667-E32667(2012)

CLPUB00507

Pultarova T.

HeLa cells: immortal space travellers.

Space Saf. Mag. 7:10-12(2013)

PubMed=23205564; DOI=10.1021/pr300859k

Malerod H., Graham R.L.J., Sweredoski M.J., Hess S.

Comprehensive profiling of N-linked glycosylation sites in HeLa cells using hydrazide enrichment.

J. Proteome Res. 12:248-259(2013)

PubMed=23336012; DOI=10.1371/journal.pone.0054672; PMCID=PMC3545996

Horvat T., Dezeljin M., Redzic I., Barisic D., Herak Bosnar M., Lauc G., Zoldos V.

Reversibility of membrane N-glycome of HeLa cells upon treatment with epigenetic inhibitors.

PLoS ONE 8:E54672-E54672(2013)

PubMed=23925224; DOI=10.1038/500141a; PMCID=PMC5101952

Hudson K.L., Collins F.S.

Biospecimen policy: family matters.

Nature 500:141-142(2013)

PubMed=23925245; DOI=10.1038/nature12064; PMCID=PMC3740412

Adey A.C., Burton J.N., Kitzman J.O., Hiatt J.B., Lewis A.P., Martin B.K., Qiu R.-L., Lee C., Shendure J.

The haplotype-resolved genome and epigenome of the aneuploid HeLa cancer cell line.

Nature 500:207-211(2013)

PubMed=24134916; DOI=10.1186/1755-8166-6-44; PMCID=PMC3879223

McCormack A., Fan J.-L., Duesberg M., Bloomfield M., Fiala C., Duesberg P.H.

Individual karyotypes at the origins of cervical carcinomas.

Mol. Cytogenet. 6:44.1-44.23(2013)

PubMed=24618588; DOI=10.1371/journal.pone.0091433; PMCID=PMC3950186

Chernobrovkin A.L., Zubarev R.A.

Detection of viral proteins in human cells lines by xeno-proteomics: elimination of the last valid excuse for not testing every cellular proteome dataset for viral proteins.

PLoS ONE 9:E91433-E91433(2014)

PubMed=24696503; DOI=10.1074/mcp.M113.035170; PMCID=PMC4047476

Guo X.-F., Trudgian D.C., Lemoff A., Yadavalli S., Mirzaei H.

Confetti: a multiprotease map of the HeLa proteome for comprehensive proteomics.

Mol. Cell. Proteomics 13:1573-1584(2014)

PubMed=24908793

Gilgenkrantz S.

Sixty years of HeLa cell cultures.

Hist. Sci. Med. 48:139-144(2014)

PubMed=25960936; DOI=10.4161/21624011.2014.954893; PMCID=PMC4355981

Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.

A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.

OncoImmunology 3:e954893.1-e954893.12(2014)

CLPUB00376

Verspaget C.J.

Unruly bodies: monstrous readings of biotechnology.

Thesis PhD (2015); Curtin University; Perth; Australia

PubMed=25485619; DOI=10.1038/nbt.3080

Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.

A comprehensive transcriptional portrait of human cancer cell lines.

Nat. Biotechnol. 33:306-312(2015)

PubMed=25807930; DOI=10.1002/anie.201500342; PMCID=PMC4471546

Broncel M., Serwa R.A., Ciepla P., Krause E., Dallman M.J., Magee A.I., Tate E.W.

Multifunctional reagents for quantitative proteome-wide analysis of protein modification in human cells and dynamic profiling of protein lipidation during vertebrate development.

Angew. Chem. Int. Ed. Engl. 54:5948-5951(2015)

PubMed=25877200; DOI=10.1038/nature14397

Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.

A resource for cell line authentication, annotation and quality control.

Nature 520:307-311(2015)

PubMed=25894527; DOI=10.1371/journal.pone.0121314; PMCID=PMC4404347

Bausch-Fluck D., Hofmann A., Bock T., Frei A.P., Cerciello F., Jacobs A., Moest H., Omasits U., Gundry R.L., Yoon C., Schiess R., Schmidt A., Mirkowska P., Hartlova A.S., Van Eyk J.E., Bourquin J.-P., Aebersold R., Boheler K.R., Zandstra P.W., Wollscheid B.

A mass spectrometric-derived cell surface protein atlas.

PLoS ONE 10:E0121314-E0121314(2015)

PubMed=26554430; DOI=10.1021/acs.analchem.5b03639

Dimayacyac-Esleta B.R.T., Tsai C.-F., Kitata R.B., Lin P.-Y., Choong W.-K., Lin T.-D., Wang Y.-T., Weng S.-H., Yang P.-C., Arco S.D., Sung T.-Y., Chen Y.-J.

Rapid high-pH reverse phase stagetip for sensitive small-scale membrane proteomic profiling.

Anal. Chem. 87:12016-12023(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878

Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Genome Med. 7:118.1-118.7(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469

Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Miroo T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

A landscape of pharmacogenomic interactions in cancer.

Cell 166:740-754(2016)

PubMed=28078501; DOI=10.1007/s11626-016-0128-8

Ambrose C.T.

The Tissue Culture Laboratory of Dr. George Otto Gey 60 yrs ago as recalled by a former student.

In Vitro Cell. Dev. Biol. Anim. 53:467-473(2017)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076

Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.

Characterization of human cancer cell lines by reverse-phase protein arrays.

Cancer Cell 31:225-239(2017)

PubMed=28261610; DOI=10.1155/2017/4180703; PMCID=PMC5316418

Kontostathi G., Zoidakis J., Makridakis M., Lygirou V., Mermelekas G., Papadopoulos T., Vougas K., Vlamis-Gardikas A., Drakakis P., Loutradis D., Vlahou A., Anagnou N.P., Pappa K.I.

Cervical cancer cell line secretome highlights the roles of transforming growth factor-beta-induced protein ig-h3, peroxiredoxin-2, and NRF2 on cervical carcinogenesis.

BioMed Res. Int. 2017:4180703.1-4180703.15(2017)

PubMed=28601559; DOI=10.1016/j.cels.2017.05.009; PMCID=PMC5493283

Bekker-Jensen D.B., Kelstrup C.D., Batth T.S., Larsen S.C., Haldrup C., Bramsen J.B., Sorensen K.D., Hoyer S., Orntoft T.F., Lindbjerg Andersen C., Nielsen M.L., Olsen J.V.

An optimized shotgun strategy for the rapid generation of comprehensive human proteomes.

Cell Syst. 4:587-599.e4(2017)

PubMed=29156801; DOI=10.18632/oncotarget.21174; PMCID=PMC5689691

Kalu N.N., Mazumdar T., Peng S.-H., Shen L., Sambandam V., Rao X.-Y., Xi Y.-X., Li L.-R., Qi Y., Gleber-Netto F.O., Patel A., Wang J., Frederick M.J., Myers J.N., Pickering C.R., Johnson F.M.

Genomic characterization of human papillomavirus-positive and -negative human squamous cell cancer cell lines.

Oncotarget 8:86369-86383(2017)

PubMed=30175587; DOI=10.1021/acs.jproteome.8b00392

Robin T., Bairoch A., Muller M., Lisacek F., Lane L.

Large-scale reanalysis of publicly available HeLa cell proteomics data in the context of the Human Proteome Project.

J. Proteome Res. 17:4160-4170(2018)

PubMed=30778230; DOI=10.1038/s41587-019-0037-y

Liu Y.-S., Mi Y., Mueller T., Kreibich S., Williams E.G., Van Drogen A., Borel C., Frank M., Germain P.-L., Bludau I., Mehnert M., Seifert M., Emmenlauer M., Sorg I., Bezrukov F., Sloan-Bena F., Zhou H., Dehio C., Testa G., Saez-Rodriguez J., Antonarakis S.E., Hardt W.-D., Aebersold R.

Multi-omic measurements of heterogeneity in HeLa cells across laboratories.

Nat. Biotechnol. 37:314-322(2019)

PubMed=30787054; DOI=10.1158/1055-9965.EPI-18-1132; PMCID=PMC6548687

Hooker S.E. Jr., Woods-Burnham L., Bathina M., Lloyd S., Gorjala P., Mitra R., Nonn L., Kimbro K.S., Kittles R.A.

Genetic ancestry analysis reveals misclassification of commonly used cancer cell lines.

Cancer Epidemiol. Biomarkers Prev. 28:1003-1009(2019)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103

Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Nature 569:503-508(2019)

PubMed=31433507; DOI=10.15252/embj.2018100847; PMCID=PMC6826212

Hardman G., Perkins S., Brownridge P.J., Clarke C.J., Byrne D.P., Campbell A.E., Kalyuzhnyy A., Myall A., Eyers P.A., Jones A.R., Eyers C.E.

Strong anion exchange-mediated phosphoproteomics reveals extensive human non-canonical phosphorylation.

EMBO J. 38:e100847.1-e100847.22(2019)

PubMed=31790455; DOI=10.1371/journal.pone.0225466; PMCID=PMC6886862

Hu W.-E., Zhang X., Guo Q.-F., Yang J.-W., Yang Y., Wei S.-C., Su X.-D.

HeLa-CCL2 cell heterogeneity studied by single-cell DNA and RNA sequencing.

PLoS ONE 14:E0225466-E0225466(2019)

PubMed=33389257; DOI=10.1007/s10096-020-04106-0; PMCID=PMC7778494

Wurtz N., Penant G., Jardot P., Duclos N., La Scola B.

Culture of SARS-CoV-2 in a panel of laboratory cell lines, permissivity, and differences in growth profile.

Eur. J. Clin. Microbiol. Infect. Dis. 40:477-484(2021)"